|
Cardioneuroablation for Bradyarrhythmia
RECRUITINGN/ASponsored by Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Actively Recruiting
PhaseN/A
SponsorFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Started2024-03-04
Est. completion2026-02-01
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06288633
Summary
This is a multicenter prospective randomized blind controlled trial with a sham procedure group of the efficacy and safety of cardioneuroablation as a method of treating symptomatic bradycardia without a permanent pacemaker implantation
Eligibility
Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Any of the following variants of bradyarrhythmia in patients aged 18-65 years: (1.1.) Symptomatic sinus bradycardia or bradycardia due to atrioventricular blockade, including transient. (1.2.) Severe asymptomatic sinus bradycardia with a rhythm frequency of \<30 beats/min. (1.3.) Transient atrioventricular block of II-III degree or permanent block of II degree. (1.4.) Repeated fainting or pre-fainting states with a proven association with bradycardia (without injury). (1.5.) Rhythm pauses \>6 seconds. In combination with the following two criteria: 2. Positive reaction to physical activity and/or atropine test: (2.1.) Increase in sinus rhythm frequency ≥25% or \>90 beats/min. (2.2.) The transition of atrioventricular blockade of the II-III degree to the 1st degree or complete normalization of atrioventricular conduction at the sinus rhythm. 3. Sinus rhythm at the time of switching on Exclusion Criteria: 1. Anamnesis of injury during syncopation due to bradycardia, except in the case when the patient refused to implant an electrocardiostimulator for his own reasons in writing; 2. Constant intake of antiarrhythmic drugs (for PVC, AF, etc.); 3. The presence of an implanted pacemaker, a heart contractility modulation device, a cardioverter defibrillator; 4. Drug-induced sinus bradycardia and/or atrioventricular block; 5. Bradycardia due to electrolyte imbalance (e.g. hyperkalemia); 6. Bradycardia due to hypothyroidism or other reversible conditions; 7. No reaction to the administration of atropine (up to a maximum dose of 0.2 mg / kg); 8. Proven association of bradyarrhythmia with episodes of apnea/hypopnea in obstructive sleep apnea syndrome; 9. Clinically significant coronary artery disease; 10. Postinfarction cardiosclerosis; 11. Hemodynamically significant congenital heart defects, including operated ones; 12. Stroke or transient ischemic attack \<3 months; 13. Open heart surgery in the anamnesis; 14. Catheter interventions on coronary arteries or for cardiac arrhythmias \<3 days; 15. Conditions after percutaneous coronary angioplasty \<3 months; 16. Anamnesis of stable ventricular tachycardia on the background of bradycardia; 17. Pregnancy or breastfeeding period
Conditions4
BradycardiaHeart DiseaseSick Sinus SyndromeSyncope
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Started2024-03-04
Est. completion2026-02-01
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06288633